Clinical Trial Update: Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial evaluating sacituzumab govitecan-hziy in combination with pembrolizumab versus physician's choice in triple-negative breast cancer pa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Keytruda (Pembrolizumab) (pembrolizumab)
• Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan-hziy)

Snippet

Sponsor: Gilead Sciences | Conditions: Triple Negative Breast Cancer | Phase 3 | Status: RECRUITING